7 July 2025 - The SMC which advises on newly licensed medicines for use by NHSScotland, has today published advice on eight medicines.

Selpercatinib (Retsevmo) was accepted for the treatment of patients, 12 years and older, with thyroid cancer that is advanced and caused by mutations in a gene called RET.

Read SMC press release